From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Abstract

Traditional cancer therapy methods, especially those directed against specific intracellular targets or signaling pathways, are not powerful enough to overcome tumor heterogeneity and therapeutic resistance. Oncolytic peptides that can induce membrane lysis-mediated cancer cell death and subsequent anticancer immune responses, has provided a new paradigm for cancer therapy. However, the clinical application of oncolytic peptides is always limited by some factors such as unsatisfactory bio-distribution, poor stability, and off-target toxicity. To overcome these limitations, oncolytic polymers stand out as prospective therapeutic materials owing to their high stability, chemical versatility, and scalable production capacity, which has the potential to drive a revolution in cancer treatment. This review provides an overview of the mechanism and structure-activity relationship of oncolytic peptides. Then the oncolytic peptides-mediated combination therapy and the nano-delivery strategies for oncolytic peptides are summarized. Emphatically, the current research progress of oncolytic polymers has been highlighted. Lastly, the challenges and prospects in the development of oncolytic polymers are discussed.

Graphical abstract

Highlights

• •

  Tumor heterogeneity and therapeutic resistance can be circumvented by oncolytic peptides/polymers.

• •

  ●History of the development from oncolytic peptides to oncolytic polymers is systematically reviewed.

• •

  ●The unique advantages and future research directions of oncolytic polymers are discussed.

• •

  ●The possible challenges and related approaches in the development of oncolytic polymers are discussed.